Convergence of Artificial Intelligence (AI), Machine Learning and Proteins Active in the Tumor Microenvironment

OTraces’ founder and CEO Keith Lingenfelter has been an in vitro diagnostic industry innovator and pioneer for many years. As a senior officer at IGEN International, Inc. in the ‘90s, he developed electrochemiluminesene (ECL) as a diagnostic tool, which was sold to Roche for $1.5 billion in 2003 where it became the nucleus for Roche’ successful Elecsys^TM platform for volume screening platform.

Starting with the founding of OTraces in 2008, Mr. Lingenfelter has led in the development of OTrace’s core technology which apples the principals of math- and physics-based measure science to in vitro cancer detection and high volume screening for the first time.

OTraces Inc. Videos

OTraces` New Cancer Detection Technology Goes Beyond Liquid Biopsy (ver. April 20, 2018) - Video